Real-time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic model by in vivo flow cytometry assesses resection on metastasis

Cancer Research

Volumn 72, Issue 10, 2012, Pages 2683-2691

  Fan, Zhi Chao ^a   Yan, Jun ^a,c   Liu, Guang Da ^a   Tan, Xiao Ying ^a   Weng, Xiao Fu ^b   Wu, Wei Zhong ^a   Zhou, Jian ^a   Wei, Xun Bin ^a,b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c FUJIAN PROVINCIAL TUMOR HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CANCER SURGERY; CARCINOMA CELL; CELL COUNT; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DISTANT METASTASIS; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; SENSITIVITY AND SPECIFICITY;

EID: 84861157373     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3733     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM,Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Tang ZY. Hepatocellular carcinoma surgery: review of the past and prospects for the 21st century. J Surg Oncol 2005;91:95-6.
3. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005;23:2892-9. (Pubitemid 46224106)
4. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91. (Pubitemid 39095313)
5. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-30.
6. Muller V, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E, et al. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. Breast Cancer Res 2011;13:R71.
7. Andreopoulou E, Cristofanilli M. Circulating tumor cells as prognostic marker in metastatic breast cancer. N Engl J Med 2010;10:171-7.
8. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006;12:4218-24.
9. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13:920-8. (Pubitemid 46340368)
10. Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Dieras V, Mathiot C, Mignot L, et al. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 2008;19:496-500. (Pubitemid 351325670)
11. Novak J, Georgakoudi I, Wei X, Prossin A, Lin CP. In vivo flow cytometer for real-time detection and quantification of circulating cells. Opt Lett 2004;29:77-9.
12. Novak J, Puoris0haag M. Two-color, double-slit in vivo flow cytometer. Opt Lett 2007;32:2993-5. (Pubitemid 351302852)
13. Zhong CF, Tkaczyk ER, Thomas T, Ye JY, Myc A, Bielinska AU, et al. Quantitative two-photon flow cytometry-in vitro and in vivo. J Biomed Opt 2008;13:59801.
14. Fan Z, Spencer JA, Lu Y, Pitsillides CM, Singh G, Kim P, et al. In vivo tracking of 'color-coded' effector, natural and induced regulatory T cells in the allograft response. Nat Med 2010;16:718-22.
15. He W, Wang HF, Hartmann LC, Cheng JX, Low PS. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc Natl Acad Sci U S A 2007;104:11760-5. (Pubitemid 47175086)
16. Sipkins DA, Wei X,WuJW, Runnels JM, Cote D, Means TK, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumor engraftment. Nature 2005;435:969-73. (Pubitemid 40896324)
17. Georgakoudi I, Solban N, Novak J, Rice WL, Wei X, Hasan T, et al. In vivo flow cytometry: a new method for enumerating circulating cancer cells. Cancer Res 2004;64:5044-7. (Pubitemid 39006514)
18. Li Y, Fan ZC, Guo J, Liu GD, Tan XY, Wang C, et al. Circulation times of hepatocellular carcinoma cells by in vivo flow cytometry. Chin Opt Lett 2010;10:953-6.
19. Boutrus S, Greiner C, Hwu D, Chan M, Kuperwasser C, Lin CP, et al. Portable two-color in vivo flow cytometer for real-time detection of fluorescently-labelled circulating cells. J Biomed Opt 2007;12: 020507.
20. Lo Celso C, Fleming HE, Wu JW, Zhao CX, Miake-Lye S, Fujisaki J, et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 2009;457:92-6.
21. Tuchin VV, Tarnok A, Zharov VP. Towards in vivo flow cytometry. J Biophoton 2009;2:457-8.
22. Tuchin VV, Galanzha A, Zharov VP. In vivo image flow cytometry. In: Tuchin VV, editors. Advanced optical flow cytometry: methods and disease diagnoses. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2011. p. 387-433.
23. Tuchin VV, Tarnok A, Zharov VP. In vivo flow cytometry: a horizon of opportunities. Cytometry A 2011;79A:737-45.
24. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 2000;97:14608-13. (Pubitemid 32016623)
25. Méhes G, Witt A, Kubista E, Ambros PF. Circulating breast cancer cells are frequently apoptotic. Am J Pathol 2001;159:17-20. (Pubitemid 33704186)
26. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2003;2:S134-9.
27. BibbyMC. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 2004;40:852-7. (Pubitemid 38519764)
28. Fidler IJ. Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metast Rev 1991;10:229-43.
29. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drug 1999;17:343-59. (Pubitemid 30135902)
30. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metast Rev 1999;17:279-84. (Pubitemid 29210167)
31. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007;170:793-804. (Pubitemid 47339349)
32. Li Y, Tang ZY, Ye SL, Liu BB, Liu YK, Chen J, et al. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 2003;129:43-51. (Pubitemid 36403259)
33. Li Y, Guo J, Wang CF, Fan ZC, Liu GD, Wang C, et al. Circulation times of prostate cancer and hepatocellular carcinoma cells by in vivo flow cytometry. Cytometry A 2011;79A:848-54.
34. Feng YX, Wang T, Deng YZ, Yang P, Li JJ, Guan DX, et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 2011;53:483-92.
35. Oe H, Kaido T, Mori A, Onodera H, Imamura M. Hepatocyte growth factor as well as vascular endothelial growth factor gene induction effectively promotes liver regeneration after hepatectomy in Solt-Farber rats. Hepato- gastroenterology 2005;52:1393-7. (Pubitemid 41391000)
36. Yoon SS, Kim SH, Gonen M, Heffernan NM, Detwiller KY, Jarnagin WR, et al. Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Onco 2006;13:353-62. (Pubitemid 43255919)
37. Drixler TA, Borel Rinkes IH, Ritchie ED, van Vroonhoven TJ, Gebbink MF, Voest EE. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 2000;60:1761-5. (Pubitemid 30183453)
38. Rupertus K, Kollmar O, Scheuer C, Junker B, Menger MD, Schilling MK. Major but not minor hepatectomy accelerates engraftment of extrahepatic tumor cells. Clin Exp Metastasis 2007;24:39-48. (Pubitemid 46569336)
39. Tsuchiya Y, Sawada S, Yoshioka I, Ohashi Y, Matsuo M, Harimaya Y, et al. Increased surgical stress promotes tumor metastasis. Surgery 2003;133:547-55. (Pubitemid 36638227)
40. Menger MD, Vollmar B. Surgical trauma: hyperinflammation versus immuno-suppression? Langenbecks Arch Surg 2004;389:475-84. (Pubitemid 40022444)
41. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-3.